"The Rotarex™ Atherectomy System is designed to efficiently remove both plaque and thrombus by utilizing three distinct mechanisms of action, making it effective for treating various PAD lesions including in-stent restenosis in peripheral arteries," says Micah Watts, MD, FSIR.
“Together with the initial STORM PE results, which demonstrated faster reperfusion and improved right ventricular recovery, this 90-day data highlights significant patient centered benefits of CAVT in intermediate high risk PE,” said Robert...
“Together with the initial STORM PE results, which demonstrated faster reperfusion and improved right ventricular recovery, this 90-day data highlights significant patient centered benefits of CAVT in intermediate high risk PE,” said Robert...
iMRI enables a minimally invasive interventional practice ideal for precise soft tissue imaging, tumor targeting, biopsy and future ablation therapies, representing the future of radiation-free, image-guided care.
iMRI enables a minimally invasive interventional practice ideal for precise soft tissue imaging, tumor targeting, biopsy and future ablation therapies, representing the future of radiation-free, image-guided care.
These milestones highlight what the next generation of temporary mechanical circulatory support can potentially enable; expanding access options, supporting mobility, and advancing how physicians manage critically ill patients.
These milestones highlight what the next generation of temporary mechanical circulatory support can potentially enable; expanding access options, supporting mobility, and advancing how physicians manage critically ill patients.
“Our new Institute will expand our efforts across the full spectrum of valvular heart disease,” Dr. Adams says. “Collaboration has been the foundation of our success, bringing together cardiologists, imaging specialists, anesthesiologists,...
“Our new Institute will expand our efforts across the full spectrum of valvular heart disease,” Dr. Adams says. “Collaboration has been the foundation of our success, bringing together cardiologists, imaging specialists, anesthesiologists,...
“In appropriately selected patients who survived a heart attack and do not have heart failure or left ventricular systolic dysfunction, routine continuation of beta-blockers indefinitely may not be necessary,” said Joo-Yong Hahn, MD.
“In appropriately selected patients who survived a heart attack and do not have heart failure or left ventricular systolic dysfunction, routine continuation of beta-blockers indefinitely may not be necessary,” said Joo-Yong Hahn, MD.
The study followed nearly 12,000 adults for approximately 16 years. Investigators applied AI to participants' standard coronary artery calcium scans to measure fat surrounding the heart.
The study followed nearly 12,000 adults for approximately 16 years. Investigators applied AI to participants' standard coronary artery calcium scans to measure fat surrounding the heart.
In July, Leapfrog will publicly report patient safety and quality data on thousands more ASCs on its website, allowing patients, purchasers and employers to search by procedure and compare ASCs side-by-side on evidence-based safety and...
In July, Leapfrog will publicly report patient safety and quality data on thousands more ASCs on its website, allowing patients, purchasers and employers to search by procedure and compare ASCs side-by-side on evidence-based safety and...
Treatment with enlicitide resulted in statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) compared to bempedoic acid, ezetimibe or bempedoic acid with ezetimibe at eight weeks (day 56)...
Treatment with enlicitide resulted in statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) compared to bempedoic acid, ezetimibe or bempedoic acid with ezetimibe at eight weeks (day 56)...
The study utilized Tempus Next, an AI platform that identifies significant AS or MR patients who may meet guideline-indicated therapy criteria, but do not have a treatment plan in place.
The study utilized Tempus Next, an AI platform that identifies significant AS or MR patients who may meet guideline-indicated therapy criteria, but do not have a treatment plan in place.